1. Home
  2. TECX vs RIGL Comparison

TECX vs RIGL Comparison

Compare TECX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.02

Market Cap

549.5M

Sector

N/A

ML Signal

HOLD

Logo Rigel Pharmaceuticals Inc.

RIGL

Rigel Pharmaceuticals Inc.

HOLD

Current Price

$32.91

Market Cap

564.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
RIGL
Founded
2019
1996
Country
United States
United States
Employees
60
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
549.5M
564.7M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
TECX
RIGL
Price
$30.02
$32.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$75.20
$45.67
AVG Volume (30 Days)
132.7K
278.5K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1867.68
EPS
N/A
0.44
Revenue
N/A
$294,282,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.75
P/E Ratio
N/A
$74.51
Revenue Growth
N/A
64.15
52 Week Low
$14.39
$18.14
52 Week High
$35.99
$52.24

Technical Indicators

Market Signals
Indicator
TECX
RIGL
Relative Strength Index (RSI) 54.28 62.38
Support Level $27.31 $28.14
Resistance Level $31.39 $33.09
Average True Range (ATR) 1.89 1.41
MACD 0.12 0.29
Stochastic Oscillator 71.39 75.04

Price Performance

Historical Comparison
TECX
RIGL

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Share on Social Networks: